Skip to main content
. Author manuscript; available in PMC: 2011 Sep 1.
Published in final edited form as: Clin Immunol. 2010 May 23;136(3):338–347. doi: 10.1016/j.clim.2010.04.013

Fig.2.

Fig.2

Proliferative potential of the TCR engineered CD4+CD25− and CD8+ T. The DMF5 TCR transduced CD4+CD25− (A) or CD8+ (B) cells were labeled with CFSE (panel a-day 0) and incubated for 4 days alone (panel b), with autologous mature DC (panel c), with DC pulsed with control peptide MAGE-3 (panel d) or with DC pulsed with MART-127–35 peptide (panel e). (C). Proliferation of the CFSE labeled DMF5 TCR transduced CD4+CD25− T cells when stimulated by melanoma cells. CD4F5 cells at day 0 (a) and at day 4 (b–f) incubated alone (b) or with PT-M (c), wild type A375 (d), A375 cells pulsed with exogenous MART-1 peptide (e), A375M1 (MART-1 transfected A375) (f). Representative of four separate experiments is shown.